Daicel Corporation
Stock Price Chart
2026/11/12 13:15 UpdatedPrice Trend
2026/11/12 13:15 UpdatedPrice & Trading Details
2026/11/12 13:15 UpdatedPRICE
TRADING
Analyst Recommendations 8 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/07/30 | ¥22.29 | ¥36.65 | +64.4% |
| 2026/05/12 | ¥36.95 | ¥-96.24 | -360.5% |
| 2026/02/04 | ¥50.21 | ¥64.09 | +27.7% |
| 2025/11/05 | ¥57.20 | ¥34.61 | -39.5% |
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
5.5M | +3.20% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
3.5M | +0.95% | |
|
T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Intl Discovery Fd.
|
3.0M | -2.60% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
2.2M | -2.10% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.7M | +1.33% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
932.5K | -5.62% |
Dividend History 4Years Growth
Updated 2026/11/08| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥65 | +8.3% |
| 2025 | ¥60 | +9.1% |
| 2024 | ¥55 | +22.2% |
| 2023 | ¥45 | +25.0% |
| 2022 | ¥36 | - |
Financial Performance
2026/11/08 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥467,937M | ¥538,026M | ¥558,056M | ¥586,531M |
| Gross Profit | ¥138,607M | ¥145,811M | ¥159,280M | ¥164,746M |
| Operating Income | ¥50,697M | ¥47,508M | ¥62,393M | ¥61,011M |
| Pretax Income | ¥47,644M | ¥56,399M | ¥77,698M | ¥67,480M |
| Net Income | ¥31,254M | ¥40,682M | ¥55,834M | ¥49,480M |
| EPS | ¥104.14 | ¥138.87 | ¥138.87 | ¥181.44 |
| Operating Margin | 10.83% | 8.83% | 11.18% | 10.40% |
| Balance Sheet | ||||
| Total Assets | ¥698,836M | ¥765,606M | ¥839,169M | ¥813,831M |
| Total Equity | ¥272,016M | ¥295,208M | ¥359,443M | ¥359,983M |
| Total Liabilities | ¥426,820M | ¥470,398M | ¥479,726M | ¥453,848M |
| Cash | ¥88,130M | ¥93,840M | ¥73,183M | ¥65,142M |
| Interest-bearing Debt | ¥280,502M | ¥317,832M | ¥299,790M | ¥280,919M |
| Equity Ratio | 38.92% | 38.56% | 42.83% | 44.23% |
| D/E Ratio | 1.03 | 1.08 | 0.83 | 0.78 |
| Cash Flow | ||||
| Operating CF | ¥42,993M | ¥26,847M | ¥76,729M | ¥93,406M |
| Investing CF | -¥46,528M | -¥44,093M | -¥55,374M | -¥47,869M |
| Financing CF | -¥5,452M | ¥19,956M | -¥52,373M | -¥48,855M |
| Free CF | -¥4,478M | -¥25,076M | ¥7,521M | ¥21,064M |
| Efficiency | ||||
| ROE | 11.49% | 13.78% | 15.53% | 13.75% |
| ROA | 4.47% | 5.31% | 6.65% | 6.08% |
Latest IR Information
-
Notice Regarding Results of Treasury Stock Acquisition Through Off-Board Purchase Transaction (ToSTNeT-3)
As part of capital policy under the mid-term strategy, Daicel Corporation acquired 2,376,000 shares of treasury stock for an acquisition price of 3,789,720,000 yen. The acquisition date was 2026-11-10 and the transaction method was ToSTNeT-3.
Read more -
Notice Regarding Purchase of Treasury Stock Through Off-Auction Tender Offer Trading (ToSTNeT-3)
Based on the board resolution on November 5, a treasury stock acquisition with an upper limit of 2,400,000 shares will be conducted using ToSTNeT-3 on November 10. The acquisition results will be announced after 08:45 on the same day. The...
Read more -
Notice Regarding Determination of Matters Concerning Share Buyback
As part of its medium-term strategy capital policy, and with the aim of enhancing shareholder returns and capital efficiency, Daicel Corporation will acquire up to 5,600,000 shares of common stock (2.19% of issued shares) at a total purchase price not...
Read more -
Notice of Revision to Some Numerical Targets of the Mid-Term Strategy "Accelerate 2030"
Revisions to some numerical targets of the mid-term strategy Accelerate 2030. Reflecting demand trends for Materials and High-Performance Polymers and a reassessment of capital expenditures, the company has lowered indicators such as net sales, operating income, and ROE/ROIC/ROA for fiscal...
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥1,561
Rating Score: 3.13 (Based on 8 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photoresists, optical lenses, and caprolactone derivatives; functional films and materials used in smartphones, PCs, TVs, and in-vehicle displays, polymers and solvents used in the semiconductor manufacturing process; and lenses used in VR, smartphones and various sensors. In addition, the company offers airbags inflators, pyro-fuses, and gas generators for seat belt pretensioners; acetic acid, acetic acid derivatives, acetate tow, ketene / diketene derivatives, cellulose acetate for LCD optical films, amines, and 1,3-butylene glycol; and reverse osmosis membrane and ultrafiltration membrane products, as well as water treatment systems. Further, it provides Engineering plastics comprising polyacetal, PBT resin, polybutylene terephthalate, polyphenylene sulfide, liquid crystal polymer, and cyclic olefin copolymer; AS resin, acetate plastics, water-soluble polymers, and barrier films for packaging; ABS resins, various polymer alloys, plastic compounds; Polyamide-12 and PEEK resin; and various molded containers. The company's products are used in transportation, electronics, medical care, personal care, lifestyle, everyday life, and environment and energy applications. The company was formerly known as Daicel Chemical Industries, Ltd. and changed its name to Daicel Corporation in October 2011. Daicel Corporation was incorporated in 1919 and is headquartered in Osaka, Japan.